Artikel ; Online: Diffuse Large B-Cell Lymphoma and Related Entities.
Deutsches Arzteblatt international
2023 Band 120, Heft 17, Seite(n) 289–296
Abstract: Background: Diffuse large B-cell lymphoma (DLBCL) is the most common malignant B-cell neoplasm, with an incidence of 5.6 per 100 000 persons per year and a mean age of onset of approximately 65 years. It is an aggressive type of non-Hodgkin's lymphoma ... ...
| Abstract | Background: Diffuse large B-cell lymphoma (DLBCL) is the most common malignant B-cell neoplasm, with an incidence of 5.6 per 100 000 persons per year and a mean age of onset of approximately 65 years. It is an aggressive type of non-Hodgkin's lymphoma requiring urgent treatment with curative intent. Evidence-based guidelines have not been available to date. Methods: For this first international evidence-based DLBCL-specific guideline, various systematic literature searches were performed. 5 systematic reviews, 21 randomized controlled trials (RCTs), and 36 non-randomized studies were used to formulate 42 recommendations. 142 were formulated on the basis of expert consensus. All recommendations were approved in a structured consensus-finding process. Results: For staging, combined positron emission tomography and computed tomography (PET/CT) should be performed (evidence: a prospective registry study). For all patients with a new diagnosis of DLBCL and without contraindications, R-CHOP based immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) should be initiated with curative intent (evidence: RCTs). The individual treatment strategy is tailored to the patient's age and risk constellation. Once immunochemotherapy has been completed, PET/CT should be performed again to check for remission. Patients with PET-positive residual disease that is amenable to radiotherapy should be treated with consolidating irradiation (evidence: retrospective cohort study). Conclusion: This clinical practice guideline on the diagnosis, treatment, and followup of patients with DLBCL and related entities provides a standardized clinical management approach, identifies areas where improvement would be desirable, and can serve as a basis for the development of further studies. |
|---|---|
| Mesh-Begriff(e) | Aged ; Humans ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Lymphoma, Large B-Cell, Diffuse/therapy ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Prednisone/therapeutic use ; Rituximab/therapeutic use ; Vincristine/therapeutic use |
| Chemische Substanzen | Antibodies, Monoclonal, Murine-Derived ; Cyclophosphamide (8N3DW7272P) ; Doxorubicin (80168379AG) ; Prednisone (VB0R961HZT) ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) |
| Sprache | Englisch |
| Erscheinungsdatum | 2023-03-21 |
| Erscheinungsland | Germany |
| Dokumenttyp | Journal Article ; Practice Guideline |
| ZDB-ID | 2406159-1 |
| ISSN | 1866-0452 ; 1866-0452 |
| ISSN (online) | 1866-0452 |
| ISSN | 1866-0452 |
| DOI | 10.3238/arztebl.m2023.0035 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.